Is this top FTSE 100 income stock a clear takeover candidate?

Could this company find itself a takeover target once again?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) is one of the FTSE 100’s top income champions. The company is also one of the index’s most attractive takeover targets thanks to its promising drugs pipeline and relatively low valuation multiple compared to the rest of the sector. 

Indeed, right now shares in Astra are trading at a forward enterprise value-to-earnings before interest, tax, depreciation and amortisation multiple of 11.9, compared to the UK sector average of 22.4 and US average of 14.2. 

And while Astra may be one of the UK’s largest pharma companies, the firm is actually one of the smaller large-cap pharma stocks in the global universe. For example, its market capitalisation is currently £61bn, which is around a third of that of industry giant Pfizer.

An attractive target

For some of the industry’s larger players, Astra could be an attractive acquisition target. There’s even a chance several companies could work together to buy out the business and carve up separate parts, which would could allow the acquirers to offer a higher price more likely to tempt management into a deal. 

Astra is no stranger to takeover offers, having rebuffed an offer from Pfizer nearly three years ago. However, a lot has changed since Pfizer was sent packing by the company. The biggest change has been the post-Brexit collapse in the value of sterling, which has had the effect of making UK companies look more appealing to overseas buyers. A weak sterling has essentially put a huge ‘For Sale’ sign over British companies that are now 15% cheaper for overseas buyers. 

As well as the weaker pound, Astra has also made significant progress developing its promising oncology treatments since 2014. After achieving impressive test results in tests over the past few years, it is planning to submit breast cancer drug Lynparzafor for approval in the US in the second half of the year.

If it gets the green-light from regulators, Lynparza will be the first DDR treatment on the market for breast cancer. This is just one of a number of treatments it has made significant progress with since the initial Pfizer offer. 

Its small size yet promising drugs pipeline means the company looks like a very attractive acquisition target and the company is also well placed for growth even if a buyer does not emerge. 

Income champion

As I mentioned above, Astra is one of the FTSE 100’s income champions and this means investors can pocket an attractive 4.6% dividend yield while waiting for a buyer to emerge for the company. What’s more, if no buyer does emerge, it will remain an income champion as profits from new treatments start to flow.

The payout is currently covered 1.5 times by earnings per share, leaving plenty of room for upside as growth filters through. City analysts have pencilled-in earnings per share growth of 9% for the year ending 31 December 2018 as the company’s growth picks up. Unfortunately, earnings per share are expected to slide by 15% this year, but this contraction shouldn’t threaten the payout. The shares currently trade at a forward P/E of 16.2. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »